Gilead Sciences (GILD) Net Margin Growth (1y) (2010 - 2026)
Powered by 
Analysis
Gilead Sciences (GILD) Net Margin Growth (1y) (2010 - 2026) Analysis & Trends
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Margin Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Amgen | 207.54 Bn | 193.55 Bn | 7.24 Bn | 802.00 |
| 2 | Gilead Sciences | 180.79 Bn | 177.62 Bn | 6.22 Bn | -16,220.00 |
| 3 | Vertex Pharmaceuticals | 131.64 Bn | 123.79 Bn | 2.84 Bn | -185.00 |
| 4 | Regeneron Pharmaceuticals | 81.93 Bn | 73.93 Bn | 3.93 Bn | -763.00 |
| 5 | Argenx Se | 61.25 Bn | 56.06 Bn | 1.37 Bn | 529.00 |
| 6 | Moderna | 55.42 Bn | 50.28 Bn | 52.00 Mn | 4,168.00 |
| 7 | Alnylam Pharmaceuticals | 33.27 Bn | 29.97 Bn | 992.69 Mn | 2,208.00 |
| 8 | Biogen | 31.98 Bn | 30.69 Bn | 1.96 Bn | -2,043.00 |
| 9 | Roivant Sciences | 29.95 Bn | 29.95 Bn | 1.16 Mn | -753,036.00 |
| 10 | Insmed | 28.05 Bn | 26.89 Bn | 358.27 Mn | 29,636.00 |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -16,220.00 |
| Mar 31, 2026 | 931.00 |
| Dec 31, 2025 | 836.00 |
| Sep 30, 2025 | 2,268.00 |
| Jun 30, 2025 | 447.00 |
| Mar 31, 2025 | 8,211.00 |
| Dec 31, 2024 | 364.00 |
| Sep 30, 2024 | -1,420.00 |
| Jun 30, 2024 | 748.00 |
| Mar 31, 2024 | -7,788.00 |
| Dec 31, 2023 | -220.00 |
| Sep 30, 2023 | 544.00 |
| Jun 30, 2023 | -239.00 |
| Mar 31, 2023 | 1,531.00 |
| Dec 31, 2022 | 1,691.00 |
| Sep 30, 2022 | -948.00 |
| Jun 30, 2022 | -627.00 |
| Mar 31, 2022 | -2,663.00 |
| Dec 31, 2021 | -1,562.00 |
| Sep 30, 2021 | 2,948.00 |